IntelGenx receives USPTO notice for Montelukast patent

1472153152549.png

The U.S. Patent and Trademark Office granted a notice of allowance to IntelGenx (OTCQX:IGXT; TSXV:IGX) for a patent entitled, "Device and Method of Treating Conditions Associated with Neuroinflammation."

The film formulation patent covers Montelukast oral film formulations designed for the treatment of neuroinflammation and is intended to protect IntelGenx's Montelukast VersaFilm product. 

IntelGenx's new, soon to be patented Montelukast oral film technology is designed to provide increased plasma concentration, compared with an immediate release oral tablet, with an identical loading of Montelukast. 

"The granting of this notice of allowance for a formulation specific Orange Book eligible patent for our Montelukast oral film validates the innovative work carried out on this project by our talented R&D team," Horst Zerbe, CEO of IntelGenx, said in a statement.

"While expanding our overall intellectual property portfolio, this new patent also solidifies the potential long-term market exclusivity of our unique Montelukast film product," he added

IntelGenx has several additional Montelukast-specific patent applications pending at the USPTO and foreign patent offices in relation to its proprietary Montelukast VersaFilm technology.